The podophyllotoxin derivatives VP16-213 and VM26

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

1979 • 405 citations

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1976 • 197 citations

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1976 • 187 citations

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors

1973 • 184 citations

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

VP-16–213 salvage therapy for refractory germinal neoplasms

1980 • 163 citations

cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung.

1979 • 153 citations

Etoposide (VP-16-213)

1979 • 151 citations

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.

1975 • 133 citations

4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action

1970 • 130 citations

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1974 • 118 citations

VP16-213 as a single agent in advanced testicular tumors

1980 • 112 citations

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1975 • 109 citations

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

1976 • 102 citations

Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity

1981 • 99 citations

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1975 • 97 citations

4′-Demethyl-epipodophyllotoxin-β-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

1974 • 90 citations

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1975 • 85 citations

Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.

1979 • 83 citations

Acute monoblastic leukemia: diagnosis and treatment of ten cases

1975 • 69 citations

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

1980 • 69 citations

Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia

1980 • 69 citations

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1978 • 65 citations

EPEG, a new antineoplastic epipodophyllotoxin

1975 • 64 citations

VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

1980 • 59 citations

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1977 • 58 citations

VP 16-213 in acute myelogenous leukaemia

1976 • 55 citations

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

1977 • 52 citations

Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

1982 • 50 citations

Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.

1979 • 50 citations

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.

1978 • 47 citations

Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.

1972 • 45 citations

Clinical Screening of Epipodophyllotoxin VM26 in Malignant Lymphomas and Solid Tumours

1972 • 45 citations

Single-Drug Chemotherapy of Bladder Cancer with Adriamycin, VM-26 or Bleomycin

1976 • 45 citations

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.

1976 • 45 citations

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1981 • 44 citations

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

1972 • 42 citations

PTG, a new antineoplastic epipodophyllotoxin

1975 • 36 citations

Activity of the Epipodophyllotoxin VP‐16 in the Treatment of Combination Chemotherapy‐Resistant Non‐Hodgkin Lymphoma

1978 • 35 citations

Evaluation of VP-16-213 in malignant lymphoma and melanoma.

1978 • 34 citations

4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.

1975 • 33 citations

Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.

1979 • 29 citations

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

1979 • 28 citations

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

1978 • 27 citations

Phase II clinical trial of VP-16-213 in ovarian cancer.

1981 • 26 citations

Cis‐dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non‐small cell lung cancer

1981 • 26 citations

PHASE I clinical trial of an oral solution of VP-16-213.

1976 • 25 citations

VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary

1978 • 24 citations

Epipodophyllotoxin (VP-16-213) in mycosis fungoides: A report from the Scandinavian mycosis fungoides study group

1979 • 24 citations

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

1976 • 23 citations

Phase II study of VM-26 in adult malignancies.

1980 • 23 citations

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

1974 • 23 citations

VM-26 as a second drug in the treatment of brain gliomas.

1979 • 22 citations

Experience with 4′-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis

1974 • 22 citations

Treatment of small cell bronchogenic carcinoma with VM-26.

1979 • 21 citations

Phase I trial of a new form of an oral administration of VP-16-213.

1979 • 21 citations

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.

1976 • 21 citations

Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast Cancer

1976 • 20 citations

VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy.

1981 • 20 citations

Vm-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: Preliminary report

1981 • 20 citations

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.

1981 • 20 citations

Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.

1977 • 19 citations

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors.

1975 • 17 citations

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.

1973 • 16 citations

VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

1979 • 13 citations

[Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia].

1975 • 13 citations

Use of VM-26 as a single agent in the treatment of renal carcinoma.

1979 • 11 citations

Pulmonary hyaline membrane disease occurring in the course of VM-26 therapy.

1979 • 11 citations

Phase II trial of VM-26 in patients with metastatic malignant melanoma.

1978 • 9 citations

[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].

1977 • 7 citations

VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.

1977 • 6 citations

Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.

1976 • 6 citations

Epipodophyllotoxin (VP 16-213) in the treatmetn of diffuse histiocytic lymphoma.

1975 • 3 citations